ArticleJapanese journal of radiology2026
Efficacy and safety of conventional transarterial chemoembolization for hepatocellular carcinoma using a glass membrane emulsification device: comparison with a three-way stopcock.
Article in Japanese journal of radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the efficacy and safety of conventional transarterial chemoembolization (cTACE) using a glass membrane emulsification device (GMD) versus a three-way stopcock (3WS) in treatment-naïve target lesions of hepatocellular carcinoma (HCC). MATERIALS AND
methodsWe retrospectively analyzed 54 patients (73 target lesions) treated with GMD-cTACE and 39 patients (55 target lesions) treated with 3WS-cTACE. The emulsion consisted of 5 mL of Lipiodol and 2.5 mL of an iodinated nonionic contrast medium (iomeprol 300 mg I/mL) containing 50 mg of epirubicin. The primary endpoints were the direct treatment effect on target lesions, assessed by RECICL (2015). Recurrence-free survival (RFS), safety and modified albumin-bilirubin (mALBI) grade changes were evaluated as secondary endpoints.
resultsTE4 rates were 86.3% in the GMD group and 76.4% in the 3WS group (P = 0.15). The combined TE4 + TE3 rates were 93.2% versus 83.6%, respectively (P = 0.09). The median RFS of target lesions was 1,047 days in the GMD group and 362 days in the 3WS group. RFS of target lesions tended to be longer with GMD (log-rank P = 0.058), with 1-year RFS estimates of 0.740 (GMD) and 0.470 (3WS). Restricted mean survival time (RMST) up to 365 days favored GMD (difference, 40.2 days; 95% CI, - 0.8 to 81.1; P = 0.054). Changes in hepatic reserve were not significantly different between groups.
conclusionGMD-cTACE showed numerically longer RFS of target lesions than 3WS-cTACE, with no significant between-group difference in hepatic function deterioration. Standardizing emulsion quality with GMD may improve the durability of local control in cTACE; larger prospective studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.